-
1.发明公开公开(公告)号：US20240358790A1
公开(公告)日：2024-10-31
申请号：US18684922
申请日：2022-08-19
发明人： Michael Agrez
CPC分类号： A61K38/08 , A61K9/0019 , A61K9/0053 , A61P37/04 , G01N33/6866 , G01N33/6869 , G01N2333/55 , G01N2333/57 , G01N2333/7155
摘要： The present invention related to methods and compositions for maintaining IL-2 homeostasis, including low levels CN of IL-2, in a subject, for treating autoimmune disorders. In a preferred embodiment, the composition comprises 2-amino-dodecanoic acid (2Adod)-conjugated peptides selected from RSKAKNPLYR-(2Adod)2-NH2, RSKAKNPLYR-(2ADod)4-NH2, or peptides with the same sequence where all residues are substituted with D-amino acids, conjugated to two or four 2Adod.
-
公开(公告)号：US12092634B2
公开(公告)日：2024-09-17
申请号：US17046200
申请日：2019-04-10
CPC分类号： G01N33/5306 , G01N33/6869 , G01N2333/54
摘要： Methods and compositions for detecting and quantifying cytokines are provided. The disclosed assays have reduced assay interference relative to commercially available assays and/or a control assay. The interference can be cytokine dependent, cytokine independent, or both. One embodiment provides an IL-33 immunoassay that reduces assay interference caused by endogenous soluble IL-33 binding molecules present in the sample. Exemplary soluble IL-33 binding molecules include, but are not limited to anti-IL-33 antibodies, soluble ST2 receptor, and serum components. In some embodiments a blocking agent is added to the sample to reduce, inhibit, or block IL-33 complexes in the sample from reforming after acid dissociation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.
-
公开(公告)号：US20240270819A1
公开(公告)日：2024-08-15
申请号：US17996549
申请日：2021-04-22
申请人： Elanco US Inc.
发明人： Shyr Jiann LI , Lam NGUYEN , Qingyi CHU , Fawn QIAN , Richard CHIN , Hangjun ZHAN
IPC分类号： C07K14/715 , A61K38/00 , G01N33/68
CPC分类号： C07K14/7155 , G01N33/6869 , A61K38/00 , C07K2319/21 , C07K2319/30 , G01N2333/5406 , G01N2333/5437
摘要： Provided are various embodiments relating to IL13R/IL4R contiguous polypeptides and IL13R/IL4R heterodimeric proteins from companion animal species and that bind to IL13 and/or IL4, including long-acting contiguous polypeptides and heterodimeric proteins. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.
-
4.发明公开公开(公告)号：US20240255492A1
公开(公告)日：2024-08-01
申请号：US18564642
申请日：2022-06-02
IPC分类号： G01N33/50 , C07K14/55 , C12N5/0783 , C12Q1/66 , G01N33/68
CPC分类号： G01N33/505 , C07K14/55 , C12N5/0636 , C12Q1/66 , G01N33/6869 , C12N2510/00 , G01N2333/55 , G01N2500/10
摘要： A functional cell-based potency assay for measuring the biological activity of IL-2 mutants with biased activity for the IL-2 receptor beta-gamma complex is described. In particular, the present invention relates to a Kit225 cell line that lacks expression of the IL-2 receptor alpha and its use in said functional cell-based potency assay.
-
公开(公告)号：US20240190952A1
公开(公告)日：2024-06-13
申请号：US18436802
申请日：2024-02-08
申请人： AB2 BIO SA
发明人： Greg Del Val , Eduardo Schiffrin
CPC分类号： C07K16/244 , A61K38/1709 , G01N33/6869 , A61K2039/505 , A61K2039/545 , C07K2317/30 , C07K2317/76 , C07K2317/92 , G01N2333/54
摘要： The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
-
公开(公告)号：US20240159776A1
公开(公告)日：2024-05-16
申请号：US18549183
申请日：2022-03-07
发明人： O'Bryant Sid E.
CPC分类号： G01N33/6896 , A61K45/06 , G01N33/6869 , G01N33/92 , G01N2333/525 , G01N2333/5409 , G01N2333/5412 , G01N2333/5418 , G01N2333/5428 , G01N2333/605 , G01N2333/62 , G01N2333/745 , G01N2800/2814 , G01N2800/56
摘要： The present invention includes methods for detecting neurodegeneration and treating a subject that is of Mexican American or non-Hispanic white origin, the method comprising: obtaining a blood, plasma or serum sample; determining ethnicity of the subject; measuring one or more biochemical biomarkers; or measuring one or more protein biomarkers, or measuring both biochemical biomarkers and protein biomarkers; comparing the level of expression from the sample with a statistical sample representative of the subject of Mexican American or of non-Hispanic white origin, suspected of having neurodegeneration; and treating the subject with a treatment that targets neurodegeneration or neuronal injury, wherein the neurodegeneration or neuronal injury is measured by [18F]-fluorodeoxyglucose-PET, structural MRI, or CSF total tau.
-
公开(公告)号：US20240110926A1
公开(公告)日：2024-04-04
申请号：US18257412
申请日：2021-12-15
CPC分类号： G01N33/6869 , A61K45/00 , G01N2333/525 , G01N2333/545 , G01N2800/122 , G01N2800/26 , G01N2800/52
摘要： The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1α and TNF-α cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.
-
8.发明公开公开(公告)号：US20240082358A1
公开(公告)日：2024-03-14
申请号：US17766746
申请日：2020-09-18
申请人： KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION , DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
发明人： Moon-Chang BAEK , Kyungmoo YEA , Do Kyung JUNG , Suyeon RYU , Soo Jeong NOH
CPC分类号： A61K38/2013 , A61P35/00 , G01N33/5011 , G01N33/6869 , G01N2333/55
摘要： The present invention relates to a composition containing IL-2 or an expression promoter or activator thereof as an active ingredient for prevention or treatment of cancer disease. In the present invention, it was discovered that when treating cancer cells with IL-2, an anticancer effect was enhanced by inhibiting the secretion of cancer cell-derived exosomes and the expression of PD-L1 inducing immune escape of T cells. IL-2 was also discovered to effectuate the anticancer effect directly on cancer cells compared to conventional techniques exhibiting an immune anticancer effect by activating cytotoxic T cells. Thus, IL-2 or an expression promoter or activator thereof can be advantageously used in a composition for prevention or treatment of cancer diseases.
-
公开(公告)号：US11890471B2
公开(公告)日：2024-02-06
申请号：US17506597
申请日：2021-10-20
发明人： Jacob A. Levine , Ralph J. Zitnik
CPC分类号： A61N1/36053 , G01N33/6863 , G01N33/6869 , A61N1/0456 , A61N1/3606 , A61N1/372 , A61N2/006 , A61N2007/0026 , G01N2333/525 , G01N2333/535 , G01N2333/54 , G01N2333/545 , G01N2333/5412 , G01N2333/5434 , G01N2333/57 , G01N2800/52 , G01N2800/709 , G01N2800/7095
摘要： Diagnostic screening tests that can be used to identify if a patient is a good candidates for an implantable vagus nerve stimulation device. One or more analyte, such as a cytokine or inflammatory molecule, can be measured from a blood sample taken prior to implantation of a vagus nerve stimulator to determine the patient's responsiveness to VNS for treatment of an inflammatory disorder.
-
公开(公告)号：US20230399395A1
公开(公告)日：2023-12-14
申请号：US18251303
申请日：2021-09-23
发明人： Yakun WAN , Min ZHU , Junwei GAI , Guanghui LI , Xiaoning SHEN
CPC分类号： C07K16/244 , G01N33/6869 , G01N2333/5409 , C07K2317/569 , C07K2317/76 , C07K2317/35 , C07K2317/73 , C07K2317/24 , C07K2317/92 , C07K2317/22 , C07K2317/52 , C07K2317/33
摘要： An anti-IL5 nanoantibody, and a coding sequence for coding the anti-IL5 nanoantibody, a corresponding expression vector, a host cell capable of expressing the anti-IL5 nanoantibody, and a method for producing the anti-IL5 nanoantibody are provided. The nanoantibody can specifically recognize IL5 from humans and cynomolgus monkeys, does not recognize IL5 from mice, and has a good binding activity. The nanoantibody has a good IL5/IL5R blocking activity. The blocking activity is obviously superior to that of a control antibody Nucala. The nanoantibody can effectively inhibit the proliferation of TF-1 cells induced by IL5, and the inhibition activity thereof is superior to that of the control antibody Nucala. The expression yield of the nanoantibody in Pichia pastoris can reach 13 g/L, and the purity of target protein expressed in the supernatant is high.
-
-
-
-
-
-
-
-
-
搜索结果
1321 条记录 (耗时 0.032 秒)
